Decision: Favourable

Study Title:

A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients with Relapsed Refractory Multiple Myeloma

  • NREC Code:


  • Decision:


  • Meeting Date:


  • Study Type:

    CT application

  • Principal Investigator:

    Dr Kamal Fadalla

  • PI Institution:

    St Vincent's University Hospital

  • Sponsor:

    Takeda Development Center Americas, Inc.

Scroll to Top